A 32-year-old Rh-negative woman, G3P2, presents at 30 weeks gestation with a positive indirect Coombs test (titre 1:32). She has no history of transfusion. The previous two deliveries were uncomplicated. Which investigation is most appropriate to assess the severity of fetal haemolytic disease and guide management?

## Investigation of Choice for Severity Assessment in Sensitised Rh-Negative Pregnancy ### Clinical Context This is an **already-sensitised Rh-negative woman** (positive IAT with significant titre of 1:32, which is ≥1:16) at 30 weeks gestation. The question asks for the investigation to **assess severity** of fetal haemolytic disease, not to screen for sensitisation. ### Amniocentesis with Amniotic Fluid Spectrophotometry (Liley Chart) **Key Point:** Amniocentesis allows measurement of **bilirubin concentration in amniotic fluid**, which correlates with the degree of fetal haemolysis and predicts the risk of severe anaemia, hydrops, and fetal death. **High-Yield:** - **Liley chart** (developed 1961) plots optical density difference at 450 nm (ΔOD~450~) against gestational age - **Three zones:** - **Zone 1 (low risk)**: Unaffected fetus or mild disease; repeat amniocentesis at 2–3 week intervals - **Zone 2 (intermediate risk)**: Moderate disease; repeat amniocentesis at 1–2 week intervals; consider cordocentesis - **Zone 3 (high risk)**: Severe disease; cordocentesis for fetal haemoglobin and haematocrit; in-utero transfusion if Hb <7 g/dL **Clinical Pearl:** Modern practice often uses cordocentesis (fetal blood sampling) in addition to or instead of amniocentesis, as it allows direct measurement of fetal haemoglobin, haematocrit, and reticulocyte count — providing more precise assessment of fetal anaemia and need for transfusion. ### Why This Is the Investigation of Choice 1. **Quantifies severity**: ΔOD~450~ correlates with degree of haemolysis 2. **Guides intervention**: Results determine frequency of follow-up and need for cordocentesis/transfusion 3. **Timing**: Performed from 18 weeks onward; most useful from 24 weeks when amniotic fluid bilirubin becomes detectable 4. **Established standard**: RCOG and ACOG guidelines recommend amniocentesis as first-line invasive test in sensitised pregnancies with high antibody titre ### Comparison of Investigations in Sensitised Pregnancy | Investigation | Detects | Timing | Role in Sensitised Pregnancy | |---|---|---|---| | **Indirect Coombs (IAT)** | Free anti-D antibodies in serum | Booking, 28 weeks | Identifies sensitisation; titre guides escalation | | **Amniocentesis + spectrophotometry** | Bilirubin in amniotic fluid (ΔOD~450~) | 18+ weeks, especially 24+ weeks | **Assesses severity; guides cordocentesis/transfusion** | | **Cordocentesis** | Fetal Hb, Hct, reticulocytes, direct antiglobulin test | 18+ weeks | Precise fetal anaemia assessment; therapeutic transfusion | | **Kleihauer-Betke** | Fetal cells in maternal circulation | After sensitising event or delivery | Quantifies FMH; calculates anti-D dose | | **NST / BPP** | Fetal heart rate, movements, amniotic fluid | 28+ weeks | Fetal well-being monitoring; does not assess haemolysis | **Mnemonic:** **S-A-C-K** = **Sensitised** (IAT+) → **Amniocentesis** (severity) → **Cordocentesis** (if high risk) → **Keep transfusing** (in-utero if needed). ### Management Algorithm for Sensitised Pregnancy ```mermaid flowchart TD A[Rh-negative, IAT positive, titre ≥1:16]:::outcome --> B[Amniocentesis at 24+ weeks]:::action B --> C[Measure ΔOD 450 on Liley chart]:::action C --> D{Zone on Liley chart?}:::decision D -->|Zone 1: Low risk| E[Repeat amniocentesis 2-3 weeks]:::action D -->|Zone 2: Moderate risk| F[Repeat amniocentesis 1-2 weeks]:::action F --> G{Worsening trend?}:::decision G -->|Yes| H[Cordocentesis]:::action D -->|Zone 3: High risk| H H --> I[Measure fetal Hb/Hct]:::action I --> J{Hb < 7 g/dL?}:::decision J -->|Yes| K[In-utero transfusion]:::action J -->|No| L[Repeat cordocentesis in 1-2 weeks]:::action E --> M[Continue monitoring]:::action K --> N[Deliver at 37-38 weeks or earlier if indicated]:::action ``` ### Why Other Investigations Are Insufficient **Repeat IAT and titre:** Antibody titre alone does NOT predict severity in an individual pregnancy. Two sensitised women with the same titre may have different degrees of fetal haemolysis. Titre trend (rising vs. stable) is less reliable than amniotic fluid bilirubin. **Kleihauer-Betke:** Quantifies fetal cells in maternal circulation; used to calculate anti-D dose after a sensitising event, not to assess fetal haemolysis severity. **NST and BPP:** Assess fetal well-being and exclude hydrops, but do not quantify the degree of haemolysis or guide the need for transfusion.